These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26563980)

  • 1. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
    Brastianos PK; Santagata S
    Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
    Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation is a useful marker for differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma.
    Kim JH; Paulus W; Heim S
    J Neurooncol; 2015 May; 123(1):189-91. PubMed ID: 25820214
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
    Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
    Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
    Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
    Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in BRAF mutated aggressive papillary craniopharyngioma: a case report and overview of the literature.
    Losa M; Mazza E; Pedone E; Nocera G; Liscia N; Reni M; Mortini P
    J Endocrinol Invest; 2024 Nov; 47(11):2835-2842. PubMed ID: 38696125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
    Robinson LC; Santagata S; Hankinson TC
    Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
    Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
    Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
    Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
    Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
    World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma.
    Haston S; Pozzi S; Carreno G; Manshaei S; Panousopoulos L; Gonzalez-Meljem JM; Apps JR; Virasami A; Thavaraj S; Gutteridge A; Forshew T; Marais R; Brandner S; Jacques TS; Andoniadou CL; Martinez-Barbera JP
    Development; 2017 Jun; 144(12):2141-2152. PubMed ID: 28506993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Craniopharyngioma: a roadmap for scientific translation.
    Gupta S; Bi WL; Giantini Larsen A; Al-Abdulmohsen S; Abedalthagafi M; Dunn IF
    Neurosurg Focus; 2018 Jun; 44(6):E12. PubMed ID: 29852761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.